- Published on
Pediatrics - Ewing Sarcoma
1. BASICS
Description
Ewing sarcoma is an aggressive malignant tumor of bone or soft tissue that predominantly affects children, adolescents, and young adults.
It belongs to the group of undifferentiated small round cell sarcomas and is defined by characteristic molecular abnormalities involving fusion genes that function as oncogenic transcription factors.
Principal Characteristics
Ewing sarcoma typically demonstrates:
- Rapidly proliferating malignant cells.
- Destructive bone or soft tissue growth.
- Local invasion into adjacent structures.
- Potential for early hematogenous metastasis.
- Characteristic FET–ETS gene fusions.
- Sensitivity to multiagent chemotherapy and radiotherapy.
Common Primary Sites
These include:
- Pelvis.
- Femur.
- Tibia.
- Humerus.
- Ribs and chest wall.
- Vertebral column.
- Other bones and soft tissues.
Essential Principle
Suspected Ewing sarcoma requires urgent referral to a specialized pediatric sarcoma team before biopsy, surgery, or other invasive intervention.
2. HISTORICAL TERMINOLOGY
Ewing Sarcoma of Bone
The classical form arising within bone.
Extraskeletal Ewing Sarcoma
Ewing sarcoma arising in soft tissue rather than bone.
Peripheral Primitive Neuroectodermal Tumor
Historically used for tumors with greater neural differentiation.
Askin Tumor
Historically used for Ewing sarcoma involving the thoracopulmonary region or chest wall.
Contemporary Classification
These historical variants are generally grouped under Ewing sarcoma when they share the characteristic molecular profile.
Important Distinction
Not all small round cell sarcomas previously described as Ewing-like tumors are true Ewing sarcoma.
Clinical Importance
Modern molecular classification is essential because CIC-rearranged sarcoma, BCOR-altered sarcoma, and other round cell sarcomas are biologically distinct entities.
3. EPIDEMIOLOGY
General Occurrence
Ewing sarcoma is an uncommon cancer.
Pediatric Bone Malignancy
It is one of the most common primary malignant bone tumors in children and adolescents, second to osteosarcoma in many populations.
Age
Most diagnoses occur during the second decade of life.
Median Age
Approximately 15 years.
Sex Distribution
Males are affected somewhat more frequently than females.
Geographic Variation
Incidence differs substantially among populations.
Clinical Importance
Although rare, Ewing sarcoma should be considered when an adolescent has persistent unexplained focal bone pain.
4. INCIDENCE
General Principles
Ewing sarcoma accounts for a small proportion of childhood malignancies.
United States
Approximately several hundred cases are diagnosed annually across the pediatric and young adult age spectrum.
Annual Incidence
Rates in children are commonly estimated at a few cases per million annually.
Age Distribution
Incidence increases during later childhood and adolescence.
Population Variation
Reported rates depend on:
- Age.
- Geographic region.
- Ancestry.
- Diagnostic classification.
- Cancer registry definitions.
Clinical Importance
The rarity of Ewing sarcoma contributes to delayed recognition when symptoms resemble common musculoskeletal conditions.
5. AGE DISTRIBUTION
Infancy
Ewing sarcoma is uncommon but possible.
Early Childhood
Cases occur, including extraskeletal tumors.
School-Age Children
Persistent bone pain or swelling may be the presenting feature.
Adolescence
The peak incidence occurs during adolescence.
Young Adulthood
Ewing sarcoma remains clinically important beyond the pediatric age range.
Older Adults
Uncommon presentations require careful pathological confirmation.
Clinical Importance
Age should inform clinical suspicion but must not be used to exclude the diagnosis.
6. SEX AND POPULATION PATTERNS
Sex Distribution
A modest male predominance is generally observed.
Population Differences
Ewing sarcoma is diagnosed less frequently in populations of African or East Asian ancestry than in populations of European ancestry.
Interpretation
Differences likely involve genetic susceptibility and complex population-level factors.
Clinical Importance
Population incidence patterns are not reliable enough to rule out Ewing sarcoma in an individual child.
7. RISK FACTORS
Sporadic Disease
Most cases arise without an identified predisposing clinical condition.
Genetic Susceptibility
Inherited genetic variation may influence risk.
Environmental Exposures
No specific environmental exposure has been established as a major preventable cause.
Family History
Most affected children do not have relatives with Ewing sarcoma.
Prior Cancer Therapy
Rare cases occur after treatment for another malignancy.
Clinical Importance
Ewing sarcoma is generally not caused by a child’s physical activity, a minor injury, or a recognizable lifestyle factor.
8. GENETIC SUSCEPTIBILITY
General Principles
Ewing sarcoma develops through acquired tumor-specific gene rearrangements.
Germline Variation
Certain inherited genetic variants influence susceptibility.
Familial Cancer Syndromes
Most cases are not associated with a recognizable hereditary cancer syndrome.
Hereditary Evaluation
Genetic counseling may be considered when there is:
- Strong family cancer history.
- Multiple primary malignancies.
- Unusual clinical features.
- Another indication for hereditary cancer assessment.
Important Distinction
A somatic EWSR1 fusion in tumor tissue does not mean that the alteration was inherited.
Clinical Importance
Most families do not require routine genetic testing solely because one child has Ewing sarcoma.
9. PREVENTION
General Principles
There is no established screening program that prevents Ewing sarcoma.
Lifestyle
No dietary, exercise, or supplement intervention has been shown to prevent the disease.
Routine Imaging
Not recommended for asymptomatic children.
Early Recognition
The principal practical opportunity is timely assessment of persistent suspicious symptoms.
Clinical Importance
Persistent focal bone pain, especially when associated with nighttime pain, swelling, or a mass, should not be repeatedly attributed to minor trauma without reassessment.
10. MOLECULAR PATHOGENESIS
General Principles
Ewing sarcoma is driven by characteristic chromosomal rearrangements that create oncogenic fusion proteins.
FET Family
Relevant genes include:
- EWSR1.
- FUS.
- TAF15.
ETS Family
Important fusion partners include:
- FLI1.
- ERG.
- ETV1.
- ETV4.
- FEV.
Fusion Proteins
These alter gene transcription and cellular regulatory pathways.
Cellular Consequences
Include:
- Abnormal cell proliferation.
- Impaired differentiation.
- Altered chromatin regulation.
- Malignant transformation.
Clinical Importance
Fusion-gene identification is central to confirming the modern diagnosis.
11. EWSR1::FLI1 FUSION
Description
EWSR1::FLI1 is the most frequent characteristic fusion in Ewing sarcoma.
Chromosomal Translocation
Usually results from:
t(11;22)(q24;q12).
Biological Effect
The fusion protein acts as an abnormal transcriptional regulator.
Frequency
Present in the majority of conventional Ewing sarcomas.
Diagnostic Value
Strongly supports Ewing sarcoma in the appropriate histological context.
Clinical Importance
Confirmation of EWSR1::FLI1 provides molecular evidence for the diagnosis, but the exact fusion subtype does not ordinarily determine standard treatment.
12. EWSR1::ERG AND RARE FUSIONS
EWSR1::ERG
The second most common characteristic fusion.
Chromosomal Rearrangement
Often involves chromosomes 21 and 22.
Other Fusions
Rare tumors harbor different FET–ETS combinations.
Diagnostic Testing
May require:
- RNA sequencing.
- Targeted next-generation sequencing.
- Other fusion-detection methods.
Limitations of Restricted Testing
A negative test for EWSR1::FLI1 alone does not exclude Ewing sarcoma.
Clinical Importance
A broad molecular testing strategy may be necessary when the morphology suggests Ewing sarcoma but common fusion testing is negative.
13. EWING SARCOMA VERSUS EWING-LIKE SARCOMAS
General Principles
Several molecularly distinct sarcomas resemble Ewing sarcoma under the microscope.
CIC-Rearranged Sarcoma
Often involves CIC gene fusions and may behave aggressively.
BCOR-Altered Sarcoma
Includes tumors with BCOR-related genetic abnormalities.
EWSR1 Non-ETS Round Cell Sarcoma
Contains EWSR1 fusions involving partners outside the classical ETS family.
Diagnostic Importance
These entities may differ in:
- Biology.
- Treatment response.
- Prognosis.
- Clinical trial eligibility.
Clinical Importance
EWSR1 rearrangement detected by break-apart FISH alone is not sufficient to classify every small round cell tumor as Ewing sarcoma.
14. HISTOGENESIS AND TUMOR BIOLOGY
General Principles
The precise normal cell of origin remains an area of investigation.
Small Round Cell Morphology
Tumors typically contain relatively uniform malignant cells.
Proliferation
Growth may be rapid.
Local Invasion
Malignant cells may spread through bone and surrounding soft tissues.
Micrometastatic Disease
Occult systemic tumor cells may be present despite apparently localized imaging.
Clinical Importance
The likelihood of occult systemic disease explains why chemotherapy is essential even when the primary tumor appears completely resectable.
15. PRIMARY TUMOR SITES
Common Skeletal Sites
These include:
- Pelvic bones.
- Femur.
- Tibia.
- Fibula.
- Humerus.
- Ribs.
- Vertebrae.
Soft Tissue Sites
May include:
- Trunk.
- Extremities.
- Thoracic soft tissues.
- Retroperitoneum.
- Other locations.
Site-Dependent Symptoms
Presentation depends on local anatomy.
Clinical Importance
Tumor location affects biopsy planning, surgical feasibility, radiation decisions, and prognosis.
16. PELVIC EWING SARCOMA
General Principles
The pelvis is a common primary site.
Presenting Symptoms
May include:
- Hip pain.
- Buttock pain.
- Back pain.
- Limping.
- Pelvic mass.
- Difficulty walking.
Diagnostic Challenges
Deep tumors may not produce an obvious palpable mass.
Potential Local Effects
These include:
- Compression of nerves.
- Compression of pelvic organs.
- Reduced mobility.
Clinical Importance
Unexplained persistent hip or pelvic pain warrants appropriate imaging when the clinical course is atypical.
17. FEMORAL AND LONG-BONE DISEASE
General Principles
Long-bone Ewing sarcoma frequently involves the diaphysis or metadiaphysis.
Symptoms
These include:
- Localized pain.
- Swelling.
- Reduced activity.
- Limp.
- Tenderness.
Pathological Fracture
May occur when tumor destruction weakens bone.
Soft Tissue Extension
A mass may develop adjacent to the affected bone.
Clinical Importance
Long-bone lesions require careful evaluation for both local tumor extent and risk of fracture.
18. CHEST WALL EWING SARCOMA
Historical Term
Askin tumor has been used for Ewing sarcoma of the chest wall.
Typical Structures
May arise from:
- Ribs.
- Chest wall soft tissues.
- Adjacent thoracic tissues.
Symptoms
These may include:
- Chest wall pain.
- Palpable mass.
- Cough.
- Dyspnea.
- Pleural symptoms.
Local Extension
May involve the pleura or nearby thoracic structures.
Clinical Importance
Chest wall tumors require coordinated surgical, radiation, and pediatric oncology planning.
19. VERTEBRAL AND PARASPINAL DISEASE
General Principles
Ewing sarcoma may arise in vertebral or paraspinal structures.
Symptoms
These include:
- Persistent back pain.
- Night pain.
- Radicular pain.
- Weakness.
- Sensory changes.
Spinal Canal Extension
May cause compression of the spinal cord or nerve roots.
Emergency Features
These include:
- Progressive weakness.
- Gait deterioration.
- Bladder dysfunction.
- Bowel dysfunction.
Clinical Importance
Suspected spinal cord compression is an oncological emergency requiring immediate MRI and specialist assessment.
20. EXTRASKELETAL EWING SARCOMA
Description
Extraskeletal Ewing sarcoma originates in soft tissue without a primary bone origin.
Common Locations
May include:
- Extremities.
- Trunk.
- Thorax.
- Pelvis.
- Other soft tissues.
Presentation
Often involves a growing mass.
Imaging
MRI defines local extent and relationships to neurovascular structures.
Diagnosis
Requires the same rigorous molecular confirmation as skeletal Ewing sarcoma.
Clinical Importance
Extraskeletal disease is treated using similar multimodal principles but local-control decisions depend on anatomical location.
21. METASTATIC SPREAD
General Principles
Ewing sarcoma has a strong tendency for hematogenous dissemination.
Common Metastatic Sites
These include:
- Lung.
- Bone.
- Bone marrow.
Less Common Sites
May include:
- Regional lymph nodes.
- Central nervous system.
- Other organs.
Metastatic Presentation
Approximately one-quarter of patients have detectable metastases at diagnosis, depending on the population and staging methods.
Clinical Importance
Metastatic status at diagnosis is one of the strongest predictors of prognosis.
22. PULMONARY METASTASES
General Principles
The lungs are a common site of metastatic disease.
Clinical Presentation
Pulmonary metastases may be asymptomatic.
Advanced Disease
May cause:
- Cough.
- Dyspnea.
- Chest discomfort.
- Pleural symptoms.
Diagnosis
Chest CT is essential for staging.
Treatment
May involve systemic chemotherapy and selected pulmonary-directed local treatment.
Clinical Importance
Normal chest radiography does not adequately exclude pulmonary metastases at initial staging.
23. BONE METASTASES
General Principles
Ewing sarcoma may spread to distant skeletal sites.
Symptoms
Possible manifestations include:
- Multifocal bone pain.
- Limping.
- Pathological fractures.
- Functional impairment.
Detection
FDG-PET imaging is an important staging modality.
Alternative Imaging
Bone scintigraphy may be used in selected settings.
Clinical Importance
Bone metastatic disease generally indicates a higher-risk presentation than isolated localized disease.
24. BONE MARROW INVOLVEMENT
General Principles
Malignant cells may infiltrate bone marrow.
Clinical Findings
Possible manifestations include:
- Anemia.
- Thrombocytopenia.
- Fatigue.
- Bleeding.
- Leukopenia.
Laboratory Findings
CBC abnormalities may raise suspicion.
Diagnostic Methods
May include marrow sampling in selected patients.
Contemporary Approach
Routine bilateral marrow biopsy may be omitted in some patients with otherwise localized disease after high-quality PET-based staging.
Clinical Importance
Bone marrow biopsy is no longer universally mandatory for every newly diagnosed patient when modern imaging adequately evaluates metastatic disease.
25. SKIP LESIONS
Description
Skip lesions are separate tumor deposits within the same bone or nearby skeletal compartment, discontinuous from the primary tumor.
Importance
May alter:
- Surgical planning.
- Radiation field.
- Assessment of local disease extent.
MRI
Imaging of the entire involved bone is important.
Clinical Importance
Local MRI must extend beyond the immediately visible mass to identify discontinuous disease.
26. CLINICAL PRESENTATION
General Principles
Symptoms depend on the primary tumor site, size, and extent.
Most Common Symptom
Persistent localized pain.
Other Presentations
These include:
- Swelling.
- Palpable mass.
- Limping.
- Reduced joint movement.
- Pathological fracture.
- Fever.
- Weight loss.
Advanced Disease
May produce systemic symptoms or organ-specific metastatic manifestations.
Clinical Importance
Early Ewing sarcoma can resemble common musculoskeletal conditions, making persistence and progression important warning signs.
27. BONE PAIN
General Principles
Bone pain is the most common presenting symptom.
Characteristics
May be:
- Persistent.
- Localized.
- Progressive.
- Worse at night.
- Present at rest.
Early Disease
Pain may initially be intermittent.
Analgesic Response
Partial improvement with pain medication does not exclude malignancy.
Clinical Importance
Progressive focal bone pain persisting despite reasonable conservative management warrants imaging and reassessment.
28. NIGHT PAIN
General Principles
Pain that wakes a child from sleep can be concerning.
Associated Features
May include:
- Local tenderness.
- Swelling.
- Limping.
- Reduced activity.
Important Limitation
Night pain is not specific to malignancy.
Clinical Importance
Persistent focal night pain, particularly with swelling or systemic symptoms, should not be dismissed as ordinary growing pains.
29. SWELLING AND PALPABLE MASS
General Principles
A soft tissue mass may develop as a tumor extends beyond bone.
Physical Features
May be:
- Firm.
- Deep.
- Tender.
- Fixed to underlying structures.
Local Warmth
May occur because of vascularity and inflammation.
Size
May increase over time.
Clinical Importance
A progressively enlarging deep mass requires urgent imaging and specialist referral.
30. FEVER AND SYSTEMIC SYMPTOMS
General Principles
Ewing sarcoma can cause systemic symptoms more commonly than some other primary bone tumors.
Possible Features
These include:
- Fever.
- Fatigue.
- Malaise.
- Weight loss.
- Reduced appetite.
- Night sweats.
Differential Diagnosis
These findings may resemble infection.
Clinical Importance
Fever and elevated inflammatory markers do not exclude Ewing sarcoma or establish osteomyelitis.
31. LIMP AND MOBILITY CHANGES
General Principles
Tumors in the pelvis or lower extremities may alter gait.
Potential Findings
These include:
- Antalgic gait.
- Avoidance of weight-bearing.
- Reduced participation in sports.
- Difficulty climbing stairs.
- Restricted joint motion.
Pathological Fracture
May produce sudden inability to bear weight.
Clinical Importance
Persistent unexplained limp in a child or adolescent requires appropriate assessment.
32. NEUROLOGICAL PRESENTATION
General Principles
Tumors near nerves or the spinal canal may produce neurological symptoms.
Symptoms
These include:
- Weakness.
- Numbness.
- Radicular pain.
- Gait disturbance.
- Bowel dysfunction.
- Bladder dysfunction.
Urgent Evaluation
Suspected spinal compression requires immediate MRI.
Clinical Importance
Neurological deterioration should not wait for routine outpatient oncology assessment.
33. PATHOLOGICAL FRACTURE
Description
A pathological fracture occurs through bone weakened by tumor.
Presentation
May include:
- Sudden severe pain.
- Deformity.
- Swelling.
- Inability to bear weight.
Management
Requires:
- Immobilization.
- Analgesia.
- Orthopedic oncology assessment.
- Tumor-specific treatment planning.
Important Precaution
Unplanned internal fixation can contaminate tissue planes and complicate definitive local control.
Clinical Importance
Suspected malignant pathological fracture should be managed through an orthopedic oncology team before definitive fixation whenever feasible.
34. HISTORY
General Principles
History should characterize the lesion and identify possible systemic or neurological involvement.
Pain
Document:
- Location.
- Duration.
- Progression.
- Night symptoms.
- Relation to activity.
Swelling
Ask when a mass was first noticed.
Trauma
Determine whether a preceding injury adequately explains the symptoms.
Functional Changes
Review:
- Limping.
- School attendance.
- Sports participation.
- Daily activities.
Systemic Features
Ask about fever, weight loss, and fatigue.
Clinical Importance
A minor injury may draw attention to a preexisting lesion rather than cause the malignancy.
35. PHYSICAL EXAMINATION
General Principles
Examination should assess local disease and possible neurological or systemic complications.
General Assessment
Include:
- Vital signs.
- Growth.
- Nutritional status.
- General appearance.
Local Examination
Assess:
- Tenderness.
- Swelling.
- Mass size.
- Skin changes.
- Range of motion.
Neurovascular Examination
Evaluate distal pulses, sensation, and motor function.
Spine
Assess neurological findings when axial disease is suspected.
Clinical Importance
Avoid vigorous palpation or manipulation of a potentially weakened bone.
36. RED FLAGS
Persistent Focal Bone Pain
Especially if progressive.
Night Pain
Particularly when associated with other abnormal findings.
Increasing Mass
A deep, enlarging swelling is concerning.
Pathological Fracture
Requires urgent orthopedic oncology evaluation.
Unexplained Limp
Especially with focal tenderness.
Fever and Bone Destruction
May represent infection or malignancy.
Neurological Deficits
May indicate spinal compression.
Clinical Importance
Suspicious imaging findings or a persistent unexplained bone lesion require referral to a sarcoma center before biopsy or surgery.
37. DIFFERENTIAL DIAGNOSIS
Malignant Conditions
These include:
- Osteosarcoma.
- Lymphoma of bone.
- Leukemia.
- Rhabdomyosarcoma.
- CIC-rearranged sarcoma.
- BCOR-altered sarcoma.
- Neuroblastoma metastasis.
- Other soft tissue sarcomas.
Benign or Nonmalignant Conditions
These include:
- Osteomyelitis.
- Stress fracture.
- Traumatic injury.
- Langerhans cell histiocytosis.
- Benign bone tumors.
- Chronic recurrent multifocal osteomyelitis.
Clinical Importance
Imaging alone cannot always distinguish Ewing sarcoma from infection or other malignancy.
38. OSTEOMYELITIS
General Principles
Osteomyelitis can closely resemble Ewing sarcoma.
Shared Features
These include:
- Bone pain.
- Fever.
- Swelling.
- Elevated inflammatory markers.
- Destructive radiographic lesions.
Diagnostic Challenges
Both can produce periosteal reaction and adjacent soft tissue abnormalities.
Important Distinction
Failure to improve with appropriate infection treatment requires reassessment.
Clinical Importance
A destructive bone lesion should not undergo unplanned surgical drainage or prolonged empirical antibiotic treatment without considering malignancy.
39. OSTEOSARCOMA
General Principles
Osteosarcoma is another important primary malignant bone tumor in adolescents.
Typical Location
Often involves the metaphysis of long bones.
Imaging
May show osteoid-producing matrix and aggressive periosteal reaction.
Histology
Malignant osteoid production supports osteosarcoma.
Ewing Sarcoma
More often demonstrates small round cells and characteristic fusion genes.
Clinical Importance
Correct histological classification is essential because the chemotherapy regimens differ.
40. SMALL ROUND CELL SARCOMAS
General Principles
Several sarcomas share the appearance of small round malignant cells.
Important Entities
Include:
- Ewing sarcoma.
- CIC-rearranged sarcoma.
- BCOR-altered sarcoma.
- Desmoplastic small round cell tumor.
- Some rhabdomyosarcomas.
Diagnostic Tools
Require integration of:
- Morphology.
- Immunohistochemistry.
- Molecular pathology.
Clinical Importance
An undifferentiated round cell tumor should not be treated as conventional Ewing sarcoma without appropriate diagnostic confirmation.
41. INITIAL IMAGING
General Principles
Plain radiographs are usually the first imaging investigation for persistent focal bone symptoms.
Standard Views
Obtain at least two orthogonal views when appropriate.
Suspicious Features
These include:
- Aggressive bone destruction.
- Permeative or moth-eaten appearance.
- Periosteal reaction.
- Soft tissue mass.
- Cortical destruction.
Next Step
Urgent MRI and sarcoma specialist referral.
Clinical Importance
Normal or equivocal early radiographs do not completely exclude a malignant bone lesion when symptoms persist.
42. PLAIN RADIOGRAPHIC FINDINGS
Permeative Destruction
Multiple small areas of bone destruction may create a moth-eaten pattern.
Periosteal Reaction
May be aggressive and layered.
Onion-Skin Appearance
Reflects successive layers of periosteal new bone formation.
Codman Triangle
Raised periosteum may create an angular reactive bone appearance.
Cortical Destruction
May be visible in advanced lesions.
Soft Tissue Component
May accompany bone abnormalities.
Clinical Importance
The onion-skin appearance is suggestive but not specific for Ewing sarcoma.
43. MRI OF THE PRIMARY SITE
General Principles
MRI is the preferred modality for defining local tumor extent.
Assessment
Should characterize:
- Intramedullary tumor extent.
- Soft tissue extension.
- Neurovascular involvement.
- Joint relationships.
- Adjacent structures.
- Skip lesions.
Contrast
Contrast-enhanced sequences may aid characterization and biopsy targeting.
Field of View
For long-bone disease, imaging the full involved bone and relevant adjacent joints is important.
Clinical Importance
MRI should generally be completed before biopsy to support accurate staging and procedural planning.
44. CT OF THE PRIMARY SITE
General Principles
CT can complement MRI.
Potential Uses
These include:
- Defining cortical bone destruction.
- Evaluating complex pelvic bone anatomy.
- Surgical planning.
- Assessing mineralization.
Limitations
MRI is generally superior for soft tissue and marrow extent.
Radiation Exposure
Consider cumulative radiation in pediatric patients.
Clinical Importance
CT should address a specific diagnostic or planning question rather than replace comprehensive MRI.
45. METASTATIC STAGING
General Principles
Complete staging is required before definitive treatment.
Main Objectives
Determine:
- Primary tumor extent.
- Pulmonary metastases.
- Skeletal metastases.
- Bone marrow involvement.
- Other metastatic sites when suspected.
Standard Investigations
Typically include:
- Chest CT.
- FDG-PET/CT or another suitable whole-body staging modality.
- MRI of the primary region.
Clinical Importance
The distinction between localized and metastatic disease is central to treatment planning and prognosis.
46. CHEST CT
General Principles
Chest CT is the principal imaging modality for detecting pulmonary metastases.
Findings
May demonstrate:
- Pulmonary nodules.
- Pleural abnormalities.
- Other thoracic involvement.
Indeterminate Nodules
Small nodules may be difficult to classify.
Follow-Up
Requires multidisciplinary interpretation.
Clinical Importance
Not every small pulmonary nodule is metastatic, but suspicious findings must be incorporated into staging decisions.
47. FDG-PET IMAGING
General Principles
Fluorodeoxyglucose PET evaluates metabolically active disease.
Uses
Include:
- Initial metastatic staging.
- Detection of skeletal lesions.
- Selected response assessment.
- Investigation of suspected recurrence.
PET/CT
Provides anatomical and metabolic information.
Limitations
Inflammation can produce false-positive uptake.
Small lesions may be missed.
Clinical Importance
PET is an important contemporary staging tool, particularly for skeletal metastatic disease.
48. BONE SCINTIGRAPHY
General Principles
Technetium-based bone scintigraphy has historically been used to detect skeletal metastases.
Contemporary Role
May be used when PET imaging is unavailable or unsuitable.
Limitations
Sensitivity and specificity vary by lesion characteristics.
Clinical Importance
PET-based staging has reduced the routine need for bone scans in many centers.
49. BONE MARROW ASPIRATION AND BIOPSY
Historical Approach
Bilateral marrow aspirates and biopsies were routinely performed in many staging protocols.
Contemporary Practice
Modern PET-based imaging can detect many clinically important marrow and skeletal lesions.
Selected Omission
Marrow sampling may be omitted in selected patients with otherwise localized disease after high-quality staging.
Indications for Sampling
Consider when:
- Imaging is suspicious.
- Blood counts are abnormal.
- Protocols require it.
- Findings would alter treatment.
Clinical Importance
Bone marrow sampling should be individualized rather than assumed mandatory in every patient.
50. DIAGNOSTIC BIOPSY PLANNING
General Principles
Biopsy must be planned by the sarcoma team responsible for definitive local treatment.
Objectives
Obtain sufficient tissue while avoiding unnecessary contamination.
Biopsy Tract
Should be positioned so that it can be removed during definitive surgery when feasible.
Important Precautions
Avoid:
- Unplanned transverse incisions.
- Contamination of multiple compartments.
- Injury to major neurovascular structures.
- Inadequate tissue acquisition.
Clinical Importance
An improperly planned biopsy can jeopardize limb-salvage surgery and compromise local tumor control.
51. BIOPSY TECHNIQUES
Image-Guided Core Biopsy
Often appropriate when performed by an experienced interventional radiologist and sarcoma team.
Open Biopsy
May be needed when core biopsy is insufficient.
Tissue Handling
Samples should be allocated for:
- Histology.
- Immunohistochemistry.
- Molecular testing.
- Additional studies when indicated.
Repeat Biopsy
Occasionally required if the original tissue is nondiagnostic.
Clinical Importance
Obtaining enough tissue for molecular confirmation is essential.
52. HISTOPATHOLOGY
General Principles
Conventional Ewing sarcoma typically appears as a malignant small round blue cell tumor.
Microscopic Features
Often include:
- Relatively uniform small round cells.
- High nuclear-to-cytoplasmic ratio.
- Fine chromatin.
- Scant cytoplasm.
- Variable necrosis.
Glycogen
Tumor cells may contain cytoplasmic glycogen.
Morphological Variability
Some tumors show atypical or differentiated features.
Clinical Importance
Morphology is suggestive but insufficient for modern definitive classification without supporting immunophenotypic and molecular evidence.
53. IMMUNOHISTOCHEMISTRY
CD99
Often shows strong diffuse membranous expression.
NKX2.2
May provide additional support.
Other Markers
Used to exclude:
- Lymphoid malignancy.
- Rhabdomyosarcoma.
- Neuroblastoma.
- Carcinoma.
- Other small round cell tumors.
Important Limitation
CD99 is not specific for Ewing sarcoma.
Clinical Importance
CD99 positivity alone must not be used to establish Ewing sarcoma.
54. MOLECULAR CONFIRMATION
General Principles
Fusion-gene testing is strongly recommended.
Common Methods
These include:
- Fluorescence in situ hybridization.
- RT-PCR.
- RNA sequencing.
- Next-generation sequencing.
EWSR1 Break-Apart FISH
Detects EWSR1 rearrangement but does not necessarily identify the fusion partner.
RNA-Based Methods
May identify specific fusion transcripts.
Negative Results
May reflect:
- A rare fusion.
- Technical limitations.
- Another tumor entity.
Clinical Importance
Integrating molecular testing with histology is essential for accurate diagnosis.
55. LABORATORY EVALUATION
Complete Blood Count
Assesses baseline marrow function.
Kidney Function
Necessary before nephrotoxic chemotherapy.
Liver Function
Helps guide treatment safety.
Electrolytes
Assess baseline metabolic status.
Lactate Dehydrogenase
May be elevated and carries prognostic information in some studies.
Additional Testing
May include pregnancy assessment and other tests when clinically appropriate.
Clinical Importance
No blood biomarker alone establishes the diagnosis of Ewing sarcoma.
56. PRETREATMENT CARDIAC EVALUATION
General Principles
Anthracycline chemotherapy can cause cardiac injury.
Baseline Assessment
May include:
- Echocardiogram.
- Left ventricular systolic function.
- ECG when indicated.
- Cardiac history.
Risk Factors
Include prior cardiac disease or chest irradiation.
Long-Term Monitoring
Depends on cumulative treatment exposure and survivorship guidelines.
Clinical Importance
Baseline cardiac assessment is essential before doxorubicin-containing treatment.
57. PRETREATMENT FUNCTIONAL ASSESSMENT
General Principles
Document function before chemotherapy and local treatment.
Assessment
May include:
- Mobility.
- Joint range of motion.
- Neurological function.
- Pain.
- Activities of daily living.
Rehabilitation Planning
Early physical therapy assessment may be useful.
Nutrition
Review weight, dietary intake, and nutritional risks.
Clinical Importance
Baseline function supports rehabilitation planning and helps identify treatment-related changes.
58. STAGING AND RISK STRATIFICATION
Localized Disease
No detectable distant metastases on staging.
Metastatic Disease
Evidence of distant tumor spread.
Additional Prognostic Factors
These include:
- Tumor size.
- Tumor location.
- Age.
- LDH.
- Response to chemotherapy.
- Adequacy of local control.
Clinical Importance
Risk stratification should be performed by a multidisciplinary sarcoma team using the current treatment protocol.
59. TREATMENT PRINCIPLES
General Principles
Curative treatment usually requires a combination of:
- Systemic chemotherapy.
- Local control by surgery, radiation, or both.
- Additional systemic therapy after local control.
- Treatment of selected metastatic sites.
Treatment Setting
Care should occur in a specialized pediatric or adolescent and young adult sarcoma center.
Clinical Trials
Enrollment in appropriate clinical trials should be offered when available.
Clinical Importance
Surgery or radiation alone is insufficient for most patients because occult micrometastatic disease is common.
60. INTERVAL-COMPRESSED CHEMOTHERAPY
General Principles
Interval-compressed chemotherapy is a major standard treatment strategy for localized Ewing sarcoma.
Treatment Schedule
Chemotherapy cycles are generally administered approximately every two weeks when blood count recovery permits.
Regimen
Alternating combinations commonly include:
- Vincristine, doxorubicin, and cyclophosphamide.
- Ifosfamide and etoposide.
Abbreviation
VDC/IE.
Growth Factor Support
Usually required to support interval compression.
Clinical Importance
Interval-compressed VDC/IE is an established standard backbone for many children and adolescents with newly diagnosed Ewing sarcoma.
61. VDC CHEMOTHERAPY
Vincristine
A microtubule inhibitor.
Doxorubicin
An anthracycline.
Cyclophosphamide
An alkylating agent.
Principal Toxicities
Include:
- Myelosuppression.
- Nausea.
- Mucositis.
- Neuropathy.
- Cardiotoxicity.
- Hemorrhagic cystitis.
- Fertility impairment.
Administration
Doses are prescribed using protocol-specific body surface area calculations and organ function adjustments.
Clinical Importance
VDC must be administered under an oncology protocol with appropriate supportive care.
62. IE CHEMOTHERAPY
Ifosfamide
An alkylating agent.
Etoposide
A topoisomerase II inhibitor.
Principal Toxicities
Include:
- Neutropenia.
- Infection.
- Kidney tubular injury.
- Neurotoxicity.
- Hemorrhagic cystitis.
- Secondary leukemia risk.
Uroprotection
Mesna and appropriate hydration are used with ifosfamide.
Monitoring
Includes kidney function, electrolytes, neurological status, and urine assessment.
Clinical Importance
IE treatment requires close inpatient or specialized outpatient monitoring depending on the protocol.
63. CHEMOTHERAPY SCHEDULING
General Principles
Treatment is typically divided into induction and consolidation phases.
Induction
Aims to reduce primary tumor size and treat occult systemic disease.
Local Control
Usually occurs after an initial period of chemotherapy.
Consolidation
Continues systemic therapy after local treatment.
Cycle Number
Common protocols use approximately 14 cycles of interval-compressed VDC/IE, although regimen duration varies.
Important Limitation
Increasing the number of cycles does not automatically improve outcomes and may increase toxicity.
Clinical Importance
The exact schedule should follow the selected evidence-based cooperative group protocol.
64. CHEMOTHERAPY DOSE SAFETY
General Principles
Ewing sarcoma chemotherapy uses high-risk cytotoxic medications.
Dosing Basis
Typically depends on:
- Body surface area.
- Treatment protocol.
- Organ function.
- Blood count recovery.
- Prior toxicity.
Administration
Requires:
- Independent dose verification.
- Appropriate vascular access.
- Infusion precautions.
- Extravasation protocols.
Vincristine
Must only be administered intravenously using institutional safety procedures.
Clinical Importance
Chemotherapy doses must not be improvised from general mg/kg guidance or administered outside a specialized oncology service.
65. LOCAL CONTROL
General Principles
Local treatment aims to eradicate the primary tumor.
Main Approaches
These include:
- Surgery.
- Definitive radiation therapy.
- Surgery followed by radiation in selected cases.
Selection Factors
Include:
- Tumor site.
- Size.
- Neurovascular involvement.
- Expected function.
- Response to chemotherapy.
- Feasibility of negative margins.
- Long-term treatment effects.
Clinical Importance
Local-control planning should involve orthopedic oncology, radiation oncology, pediatric oncology, and relevant surgical specialists.
66. SURGICAL RESECTION
General Principles
Surgery is preferred when the tumor can be completely removed with acceptable morbidity.
Goal
Achieve negative margins while preserving as much normal function as possible.
Surgical Planning
Must consider:
- Original tumor extent.
- Response to chemotherapy.
- Biopsy tract.
- Relevant anatomical compartments.
Pathology
Resected tissue provides information on margins and chemotherapy response.
Clinical Importance
An apparently smaller tumor after chemotherapy does not justify disregarding the original tumor extent during local-control planning.
67. LIMB-SALVAGE SURGERY
General Principles
Limb salvage is frequently feasible for extremity tumors.
Techniques
May involve:
- Wide resection.
- Endoprosthetic reconstruction.
- Bone grafting.
- Allograft reconstruction.
- Other orthopedic reconstruction.
Advantages
Potential preservation of limb function.
Limitations
Complications may include:
- Infection.
- Mechanical failure.
- Nonunion.
- Growth-related problems.
Clinical Importance
Limb-salvage surgery should achieve oncological safety as well as functional benefit.
68. AMPUTATION AND ROTATIONPLASTY
General Principles
Amputation is less commonly necessary but remains appropriate in selected cases.
Indications
May include:
- Unresectable neurovascular involvement.
- Inadequate margins with limb salvage.
- Severe local complications.
- Poor expected function after reconstruction.
Rotationplasty
May be useful for selected lower limb tumors.
Rehabilitation
Requires prosthetic and physical therapy services.
Clinical Importance
The choice should prioritize survival, long-term function, and the patient’s individual goals.
69. RADIATION THERAPY
General Principles
Ewing sarcoma is radiosensitive.
Indications
Radiotherapy may be used for:
- Definitive local control.
- Positive or inadequate surgical margins.
- Selected high-risk local situations.
- Certain metastatic sites.
Techniques
May include modern conformal methods.
Treatment Planning
Requires careful consideration of:
- Tumor extent.
- Nearby critical organs.
- Growth plates.
- Long-term secondary cancer risk.
Clinical Importance
Radiotherapy is an important curative treatment option when surgery would be unsafe or excessively disabling.
70. PROTON THERAPY AND MODERN RADIATION TECHNIQUES
General Principles
Advanced radiotherapy techniques may reduce exposure of surrounding normal tissues.
Proton Therapy
May offer dosimetric advantages in selected anatomical locations.
Potential Benefits
Include reduced dose to:
- Certain organs at risk.
- Growth-sensitive structures.
- Adjacent healthy tissues.
Important Limitation
Availability and long-term comparative outcomes vary.
Clinical Importance
Modality selection should be based on individualized treatment planning rather than assuming one technique is always superior.
71. METASTATIC DISEASE TREATMENT
General Principles
Metastatic Ewing sarcoma requires systemic therapy and consideration of local treatment to the primary tumor and metastatic sites.
Chemotherapy
VDC/IE-based therapy remains an important backbone.
Local Control
May include:
- Surgery.
- Radiation.
- Selected treatment of metastatic lesions.
Lung Metastases
Whole-lung irradiation may be considered in appropriate patients.
Bone Metastases
Selected metastatic sites may receive radiation.
Clinical Importance
Metastatic treatment requires individualized multidisciplinary planning and discussion of prognosis and clinical trials.
72. WHOLE-LUNG IRRADIATION
General Principles
Whole-lung irradiation may be used in selected patients with pulmonary metastatic disease.
Purpose
Targets potential residual pulmonary microscopic disease.
Timing
Usually coordinated with systemic therapy and other local treatments.
Pediatric Considerations
Risks include:
- Pneumonitis.
- Reduced lung capacity.
- Long-term pulmonary fibrosis.
- Additional late effects.
Clinical Importance
Whole-lung irradiation decisions should consider metastatic pattern, treatment response, age, and the applicable protocol.
73. RELAPSED OR REFRACTORY EWING SARCOMA
General Principles
Relapse may occur locally, distantly, or at multiple sites.
Common Sites
Include:
- Lung.
- Bone.
- Original tumor site.
Prognosis
Relapsed disease is more difficult to cure.
Treatment Options
May include:
- Salvage chemotherapy.
- Surgery.
- Radiotherapy.
- Clinical trials.
- Symptom-directed treatment.
Clinical Importance
There is no single universally curative standard regimen for all relapsed Ewing sarcoma.
74. SALVAGE CHEMOTHERAPY
Potential Regimens
May include combinations involving:
- Irinotecan.
- Temozolomide.
- Cyclophosphamide.
- Topotecan.
- High-dose ifosfamide.
- Other agents.
Selection Factors
Include:
- Previous chemotherapy exposure.
- Interval to relapse.
- Organ function.
- Disease distribution.
- Patient preferences.
- Clinical trial availability.
Evidence
Responses occur, but long-term disease control remains challenging.
Clinical Importance
Salvage regimens should be chosen by an experienced pediatric sarcoma team.
75. INVESTIGATIONAL AND TARGETED THERAPIES
General Principles
Research is investigating treatments directed at tumor biology and immune mechanisms.
Investigational Strategies
Include:
- Novel cytotoxic combinations.
- Targeted pathway inhibitors.
- Fusion-associated therapeutic strategies.
- Immunotherapies.
- Cellular therapies.
- New radiopharmaceutical approaches.
Important Limitation
No targeted therapy has replaced VDC/IE as established initial curative systemic treatment.
Clinical Trials
Should be considered when appropriate.
Clinical Importance
Experimental approaches must be distinguished clearly from standard-of-care therapy.
76. SUPPORTIVE ONCOLOGY CARE
General Principles
Supportive care is essential throughout treatment.
Core Components
Include:
- Antiemetic therapy.
- Growth factor support.
- Infection prevention.
- Blood product support.
- Pain control.
- Nutrition.
- Rehabilitation.
- Psychosocial care.
Multidisciplinary Team
May include:
- Pediatric oncologist.
- Oncology nurse.
- Pharmacist.
- Dietitian.
- Social worker.
- Physical therapist.
- Psychologist.
Clinical Importance
Effective supportive care improves treatment tolerance and reduces preventable complications.
77. FEBRILE NEUTROPENIA
General Principles
Chemotherapy can cause profound neutropenia.
Warning Symptoms
Include:
- Fever.
- Chills.
- Ill appearance.
- New respiratory symptoms.
- Central line symptoms.
Emergency Definition
Fever in a child with chemotherapy-associated neutropenia is a medical emergency.
Management
Requires:
- Prompt assessment.
- Blood cultures.
- Empiric IV broad-spectrum antibiotics.
- Risk-based inpatient or specialized outpatient management.
Clinical Importance
Families must contact the oncology team immediately for fever during periods of neutropenia rather than treating it at home and waiting.
78. HEMATOLOGICAL SUPPORT
General Principles
Myelosuppressive chemotherapy may cause anemia and thrombocytopenia.
Red Blood Cell Transfusion
May be required for symptomatic or severe anemia.
Platelet Transfusion
May be necessary with severe thrombocytopenia, bleeding, or procedures.
Growth Factors
G-CSF supports neutrophil recovery.
Monitoring
CBC is checked according to the treatment schedule.
Clinical Importance
Transfusion decisions should follow oncology protocols and the patient’s clinical condition.
79. NAUSEA, MUCOSITIS, AND NUTRITION
General Principles
Chemotherapy can substantially affect gastrointestinal function.
Antiemetic Therapy
Typically involves protocol-based medications such as:
- 5-HT3 receptor antagonists.
- Dexamethasone when appropriate.
- Neurokinin-1 receptor antagonists for highly emetogenic treatment.
Mucositis
Requires:
- Oral care.
- Analgesia.
- Hydration.
- Infection monitoring.
Nutrition
Dietitian assessment may prevent or treat malnutrition.
Clinical Importance
Supportive treatment should be proactive rather than started only after severe symptoms develop.
80. RENAL AND BLADDER PROTECTION
General Principles
Ifosfamide and cyclophosphamide may injure the urinary tract.
Mesna
Used for uroprotection according to the chemotherapy protocol.
Hydration
Helps reduce urinary metabolite concentration.
Monitoring
Includes:
- Urine output.
- Urinalysis.
- Kidney function.
- Electrolytes.
Ifosfamide Toxicity
May cause renal tubular dysfunction and electrolyte wasting.
Clinical Importance
Hematuria, reduced urine output, or significant electrolyte abnormalities require prompt oncology assessment.
81. CARDIOTOXICITY PREVENTION
General Principles
Doxorubicin may cause cumulative cardiac injury.
Baseline Assessment
Obtain echocardiography before treatment.
Treatment Monitoring
Frequency depends on:
- Anthracycline dose.
- Symptoms.
- Cardiac risk factors.
- Institutional protocol.
Dexrazoxane
May be used as cardioprotection in selected patients according to the oncology protocol.
Long-Term Surveillance
Required according to cumulative anthracycline exposure and cardiac radiation dose.
Clinical Importance
Annual echocardiography is not universally required for every survivor; surveillance intervals should follow risk-based survivorship guidelines.
82. FERTILITY PRESERVATION
General Principles
Alkylating chemotherapy may impair future fertility.
Counseling
Should occur before starting treatment whenever feasible.
Postpubertal Boys
Sperm cryopreservation may be an option.
Postpubertal Girls
Options may include:
- Oocyte cryopreservation.
- Embryo cryopreservation in appropriate circumstances.
Prepubertal Children
Some tissue preservation approaches remain investigational or have limited availability.
Time Sensitivity
Fertility preservation must be coordinated without unsafe delays in cancer treatment.
Clinical Importance
All eligible patients and families should be offered age-appropriate fertility counseling before gonadotoxic treatment begins.
83. REHABILITATION
General Principles
Cancer and its treatment may impair mobility, strength, and endurance.
Physical Therapy
May address:
- Gait.
- Muscle weakness.
- Range of motion.
- Balance.
- Strength.
- Functional independence.
Occupational Therapy
May help with activities of daily living.
Prosthetic Services
Required after amputation or rotationplasty when indicated.
Pain Management
Supports participation in rehabilitation.
Clinical Importance
Rehabilitation should begin early and continue through survivorship when necessary.
84. PSYCHOSOCIAL SUPPORT
General Principles
A cancer diagnosis during childhood or adolescence can substantially affect emotional and social development.
Potential Concerns
Include:
- Anxiety.
- Depression.
- Body image.
- School disruption.
- Social isolation.
- Fear of recurrence.
Family Support
Caregivers may experience financial and psychological stress.
Specialist Services
May include:
- Psychology.
- Psychiatry.
- Social work.
- Peer support.
- Educational support.
Clinical Importance
Psychosocial care is a standard component of comprehensive pediatric oncology treatment.
85. PALLIATIVE CARE
General Principles
Palliative care focuses on quality of life and symptom relief.
Timing
May be appropriate from diagnosis alongside curative treatment for patients with significant symptom burden.
Services
Include:
- Pain management.
- Symptom control.
- Family counseling.
- Care coordination.
- Goals-of-care discussions.
Advanced Disease
May become particularly important when cure is unlikely.
Clinical Importance
Palliative care is not synonymous with stopping cancer treatment.
86. HOSPITAL ADMISSION
General Principles
Many treatment phases require inpatient or closely supervised specialized care.
Admission Indications
Include:
- Intensive chemotherapy.
- Febrile neutropenia.
- Severe pain.
- Pathological fracture.
- Spinal cord compression.
- Dehydration.
- Serious infection.
- Organ dysfunction.
Surgical Care
Requires perioperative monitoring.
Clinical Importance
Admission and discharge decisions should follow the oncology treatment protocol and clinical stability.
87. NURSING CONSIDERATIONS
General Principles
Oncology nursing care includes chemotherapy safety and early complication recognition.
Monitoring
Includes:
- Vital signs.
- Pain.
- Fluid balance.
- Infection signs.
- Neurological status.
- Urine output.
- Central line function.
Education
Teach families about:
- Fever precautions.
- Medication administration.
- Bleeding symptoms.
- Chemotherapy toxicity.
- Emergency contact procedures.
Clinical Importance
Specialized pediatric oncology nursing is central to safe multimodal treatment.
88. FOLLOW-UP RECOMMENDATIONS
During Treatment
Assess:
- Clinical response.
- CBC.
- Organ function.
- Chemotherapy toxicity.
- Primary tumor imaging.
After Treatment
Schedule regular visits for:
- Recurrence surveillance.
- Local functional assessment.
- Pulmonary imaging.
- Late-effect evaluation.
Early Survivorship
Visits are commonly more frequent during the first two years.
Later Survivorship
Intervals generally lengthen over time.
Clinical Importance
Follow-up should be individualized according to initial disease extent, local treatment, recurrence risk, and treatment exposures.
89. RECURRENCE SURVEILLANCE
General Principles
Relapse risk is greatest during the first several years after treatment.
Local Surveillance
May involve:
- Clinical examination.
- MRI or radiographs of the primary site.
Pulmonary Surveillance
May involve:
- Chest radiography.
- CT in selected circumstances.
Other Imaging
PET or other whole-body imaging may be indicated when recurrence is suspected.
Important Limitation
Routine intensive whole-body imaging for every survivor may increase radiation exposure without proven benefit.
Clinical Importance
A surveillance plan should balance early detection with imaging burden and long-term risk.
90. LONG-TERM SURVIVORSHIP
General Principles
Survivors require lifelong attention to treatment-related health risks.
Important Domains
Include:
- Cardiac health.
- Kidney function.
- Fertility.
- Bone and joint function.
- Pulmonary health.
- Endocrine function.
- Secondary cancers.
- Mental health.
Survivorship Plan
Should document:
- Chemotherapy agents.
- Cumulative doses.
- Radiation fields and doses.
- Surgical procedures.
- Recommended surveillance.
Clinical Importance
Late-effect monitoring should be exposure-based rather than identical for every survivor.
91. PATIENT AND FAMILY EDUCATION
General Principles
Families should understand the need for coordinated multimodal therapy.
Key Messages
Explain that:
- Ewing sarcoma is a malignant tumor.
- Chemotherapy is essential.
- Local control is also required.
- Treatment may extend over many months.
- Fever during neutropenia requires urgent action.
- Long-term follow-up is necessary.
Activity
Follow orthopedic restrictions when fracture risk exists.
Medication Safety
Avoid unapproved supplements or treatments that may interfere with chemotherapy.
Clinical Importance
Clear education supports adherence and early recognition of complications.
92. PROGNOSIS
General Outlook
Prognosis depends strongly on disease extent at diagnosis and response to treatment.
Localized Disease
Modern multimodal therapy produces five-year overall survival rates commonly approaching:
70–80%, with variation across risk groups and treatment protocols.
Metastatic Disease
Overall survival is substantially lower, often approximately:
20–40% at five years, depending on metastatic distribution and other factors.
Lung-Only Metastases
May carry a more favorable outlook than extensive bone or marrow metastases.
Bone and Marrow Metastases
Generally associated with poorer outcomes.
Tumor Location
Pelvic and axial tumors may be harder to resect adequately and may be associated with unfavorable outcomes.
Tumor Size
Large tumors carry a higher risk of treatment failure.
Age
Older adolescent and adult age may be associated with poorer outcomes in some cohorts.
LDH
Elevated pretreatment LDH can indicate greater tumor burden and may be prognostic.
Histological Response
Extensive tumor necrosis after induction chemotherapy is generally a favorable finding.
Surgical Margins
Complete local control is important.
Recurrence
Relapsed disease has a considerably worse prognosis than newly diagnosed localized disease.
Time to Relapse
Early relapse generally carries a less favorable prognosis.
Molecular Fusion Type
The common EWSR1::FLI1 fusion subtype does not ordinarily determine prognosis or routine treatment choice.
Long-Term Survival
Some survivors experience substantial treatment-related health consequences.
Clinical Importance
Modern treatment offers a realistic possibility of cure for many children with localized Ewing sarcoma, while metastatic and relapsed disease remain major therapeutic challenges.
93. COMPLICATIONS
Local Bone Destruction
Tumor growth may weaken and destroy affected bone.
Persistent Bone Pain
Pain may impair activity, sleep, and quality of life.
Pathological Fracture
Weakened bone may break with minimal trauma.
Limb Deformity
Bone destruction or treatment may alter alignment.
Joint Dysfunction
Tumor involvement or treatment may impair range of motion.
Muscle Weakness
Pain, inactivity, surgery, and chemotherapy may cause weakness.
Gait Abnormality
Lower limb disease may produce limping or altered walking patterns.
Loss of Mobility
Severe local disease may impair ambulation.
Neurological Compression
Tumors may compress peripheral nerves or the spinal cord.
Spinal Cord Compression
May cause weakness, sensory deficits, or bladder and bowel dysfunction.
Permanent Neurological Deficit
Delayed treatment of severe compression may produce lasting impairment.
Local Vascular Compression
Tumor growth may interfere with adjacent blood vessels.
Venous Obstruction
May cause swelling or thrombosis.
Local Tumor Necrosis
Rapid growth may produce necrotic tissue.
Tumor-Associated Hemorrhage
Bleeding may occur within or around a tumor.
Metastatic Pulmonary Disease
May cause respiratory symptoms or progressive lung dysfunction.
Bone Metastases
May produce additional painful skeletal lesions.
Metastatic Pathological Fractures
Distant skeletal deposits may weaken bone.
Bone Marrow Infiltration
May impair normal blood cell production.
Anemia
May result from marrow involvement or chemotherapy.
Thrombocytopenia
May cause bruising or bleeding.
Leukopenia
May reduce resistance to infection.
Severe Neutropenia
Myelosuppressive chemotherapy may cause profound neutrophil depletion.
Febrile Neutropenia
Requires urgent antimicrobial treatment.
Bacterial Sepsis
Immunosuppression may predispose to severe bloodstream infection.
Fungal Infection
Prolonged neutropenia increases risk of invasive fungal disease.
Septic Shock
Severe infection may cause circulatory failure.
Central Venous Catheter Infection
Indwelling devices may become infected.
Catheter-Associated Thrombosis
Central lines may predispose to venous clot formation.
Venous Thromboembolism
Cancer and treatment may increase thrombosis risk.
Pulmonary Embolism
Venous clots may migrate to the lungs.
Alopecia
Chemotherapy commonly causes temporary hair loss.
Nausea and Vomiting
May be severe without effective antiemetic prophylaxis.
Dehydration
Gastrointestinal toxicity may reduce fluid intake.
Mucositis
Chemotherapy may cause painful oral and gastrointestinal inflammation.
Esophagitis
Mucosal injury may impair swallowing.
Diarrhea
Chemotherapy or infection may cause gastrointestinal symptoms.
Constipation
May result from vincristine, opioid treatment, or reduced mobility.
Ileus
Vincristine-related autonomic neuropathy may impair intestinal motility.
Peripheral Neuropathy
Vincristine may cause sensory or motor nerve injury.
Foot Drop
Severe neuropathy may impair dorsiflexion.
Jaw Pain
May occur with vincristine-associated neuropathy.
Autonomic Neuropathy
Can affect bowel and bladder function.
Hemorrhagic Cystitis
Cyclophosphamide or ifosfamide metabolites may injure the bladder.
Hematuria
May result from urinary tract toxicity.
Bladder Fibrosis
Severe recurrent bladder injury may cause chronic dysfunction.
Renal Tubular Injury
Ifosfamide may impair proximal tubular function.
Fanconi Syndrome
May cause urinary losses of glucose, phosphate, bicarbonate, and other solutes.
Hypophosphatemia
Can develop from renal phosphate wasting.
Hypokalemia
May occur with renal tubular toxicity.
Metabolic Acidosis
Renal tubular dysfunction may impair acid-base balance.
Acute Kidney Injury
May result from chemotherapy, dehydration, infection, or other causes.
Chronic Kidney Disease
Severe renal injury may produce lasting impairment.
Ifosfamide Encephalopathy
May cause confusion, somnolence, hallucinations, or seizures.
Seizures
Can result from metabolic abnormalities or drug-related neurotoxicity.
Hearing or Sensory Difficulties
May occur from selected treatments or other complications.
Anthracycline Cardiotoxicity
Doxorubicin may impair myocardial function.
Cardiomyopathy
May develop during treatment or years later.
Heart Failure
Severe cardiac dysfunction may cause clinical heart failure.
Arrhythmias
May accompany cardiac toxicity.
Radiation-Associated Cardiac Injury
Thoracic irradiation may damage cardiac structures.
Pulmonary Pneumonitis
Chest irradiation may produce inflammatory lung injury.
Pulmonary Fibrosis
Radiation may cause persistent lung scarring.
Reduced Lung Capacity
Thoracic surgery or irradiation may impair pulmonary function.
Chest Wall Deformity
Resection or irradiation during growth may alter thoracic development.
Impaired Growth of Irradiated Bone
Radiation may affect growth plates and bone development.
Limb-Length Discrepancy
Surgery or radiation may alter growth in one limb.
Joint Contracture
Immobilization and fibrosis may limit movement.
Radiation Fibrosis
May cause tissue stiffness and reduced function.
Radiation Dermatitis
May cause erythema, pain, and skin injury.
Skin Breakdown
Severe local treatment effects may impair wound integrity.
Wound Dehiscence
Surgical wounds may separate.
Surgical Site Infection
May complicate reconstruction.
Osteomyelitis
Reconstructed or operated bone may become infected.
Nonunion
Reconstructed bone segments may fail to unite.
Graft Failure
Bone grafts or allografts may fail mechanically or biologically.
Endoprosthetic Failure
Implants may loosen, fracture, or become infected.
Prosthetic Revision
Growing children may require repeated reconstructive procedures.
Amputation-Related Functional Loss
May require ongoing prosthetic care.
Phantom Limb Pain
May occur after amputation.
Chronic Postsurgical Pain
May persist after local-control procedures.
Reduced Exercise Capacity
May result from deconditioning, cardiac toxicity, or musculoskeletal impairment.
Delayed Physical Development
Intensive therapy may temporarily affect normal growth and physical maturation.
Delayed Puberty
Gonadal injury or chronic illness may delay pubertal progression.
Ovarian Insufficiency
Gonadotoxic treatment may impair ovarian function.
Testicular Dysfunction
Alkylating agents may impair sperm production or hormonal function.
Reduced Fertility
May occur after chemotherapy or gonadal irradiation.
Premature Menopause
May result from severe ovarian injury.
Pregnancy-Related Risks
Certain treatment exposures may affect future reproductive health.
Endocrine Dysfunction
Radiotherapy or systemic effects may impair selected endocrine organs.
Reduced Bone Mineral Density
May result from treatment, immobility, endocrine abnormalities, or malnutrition.
Osteopenia
Low bone density may increase fracture risk.
Osteoporosis
May occur in selected long-term survivors.
Avascular Necrosis
May develop in selected treatment circumstances.
Secondary Myelodysplastic Syndrome
May occur after exposure to leukemogenic chemotherapy.
Therapy-Related Acute Myeloid Leukemia
A recognized rare late complication.
Radiation-Associated Sarcoma
May arise within a previously irradiated field years later.
Other Second Malignancies
Risk depends on chemotherapy and radiotherapy exposure.
Local Recurrence
Tumor may reappear at the original site.
Pulmonary Relapse
Recurrent metastatic disease may involve the lungs.
Skeletal Relapse
New or recurrent bone lesions may develop.
Multifocal Relapse
Disease may recur at several sites.
Treatment-Resistant Disease
Some tumors fail to respond adequately to standard chemotherapy.
Progressive Metastatic Disease
May cause multisystem morbidity.
Chronic Cancer-Related Pain
May require long-term multidisciplinary management.
Fatigue
Can persist during or after treatment.
Malnutrition
May result from treatment toxicity or reduced intake.
Anxiety
May occur during diagnosis, treatment, and survivorship.
Depression
Cancer-related distress may impair emotional well-being.
Body Image Distress
Surgery, alopecia, and visible changes may affect self-confidence.
Posttraumatic Stress Symptoms
Some patients and families develop significant treatment-related psychological distress.
School Absenteeism
Treatment may interrupt education.
Learning Difficulties
Fatigue, hospitalization, and psychosocial stress may impair academic performance.
Social Isolation
Treatment precautions and limited mobility may restrict peer interaction.
Financial Toxicity
Cancer treatment can place substantial financial pressure on families.
Caregiver Burnout
Long-term treatment demands may affect caregiver health.
Reduced Quality of Life
May result from functional limitations and treatment late effects.
Premature Mortality
May result from progressive disease, serious treatment toxicity, or late complications.
Death
Ewing sarcoma can be fatal, particularly in metastatic, treatment-resistant, or recurrent disease.